Pakistan’s Massive Genetic Database Reveals Millions of Unique Variants

The Pakistan Genome Resource (PGR), one of the largest genomic studies ever conducted in South Asia, has revealed novel insights into gene function, disease susceptibility, and the translatability of preclinical findings to humans. Published in a Nature article, a collaboration between Novartis, Columbia University Irving Medical Center, and the Center for Non-Communicable Diseases, Karachi, Pakistan, examined 173,303 PGR participants, constituting 0.07% of the population of Pakistan, the fifth most populous country in the world.

The numbers alone are impressive, as the scientists identified more than 6.6 million coding genetic variants, with nearly half of them absent from existing global databases. But the PGR is particularly powerful not just because of its size but also because of the unique genetic structure of the population being studied with high levels of familial relatedness.

The study identified naturally occurring homozygous loss-of-function (LoF) variants in 6,476 genes, about one-third of all human protein-coding genes. The researchers confirmed several well-known genetic associations. For example, individuals carrying LoF variants in the APOC3 gene had significantly lower triglyceride levels, while variants in PCSK9 were linked to lower LDL cholesterol. While both genes are already important targets in cardiovascular medicine, the findings shore up the dataset’s credibility.

New links between genes and biological traits provide clues about conditions ranging from obesity and diabetes to liver disease and neurodegeneration. In one striking example, individuals lacking a functional version of the gene CIDEB, which has become a major target in metabolic research because rare mutations that inactivate the gene provide significant protection against liver diseases, appeared to have a lower risk of liver disease, strengthening the case for therapies that target this pathway.

Some findings provided new context to genes already being widely studied, such as LRRK2—a gene currently targeted by experimental Parkinson’s disease treatments. LoF mutations in LRRK2 showed signs of kidney dysfunction. It’s an observation that raises important safety questions and highlights why human genetic studies matter so much. Sometimes biology sends a warning before a drug reaches the market.

The research also challenged assumptions based on animal studies. A gene called PRDM9 is considered essential for fertility in mice. Yet several people in the PGR with completely inactive copies of the gene had healthy children.

Ultimately, the Pakistan Genome Resource is much more than a national database. It’s a reminder that human genetic diversity remains vastly underexplored. By studying populations that have historically been overlooked, researchers are uncovering entirely new biology that could lead to better treatments, safer drugs, and a more profound understanding of what makes us human.

The post Pakistan’s Massive Genetic Database Reveals Millions of Unique Variants appeared first on Inside Precision Medicine.

Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine

We are still talking about big pharma deals and biotech fundraising in this episode. The big news this week was Parabilis Medicines’s history-making IPO. We dive into the drug developer’s plans for the eye-popping $770.5 million that it raised. Next, we discuss the details of a collaboration between Merck and Protillion Biosciences to use artificial intelligence to discover multiple therapeutic candidates. Turning to some newly published research, we discuss the early results of a first-in-human clinical trial that is testing a dual vaccine against Lassa fever and rabies, a CRISPR system engineered to selectively trigger cancer cell death by chromatin shredding, and a novel mRNA delivery platform for delivering gene therapies starting with Duchenne muscular dystrophy.

 

 

Listed below are links to the GEN stories referenced in this episode of Touching Base:

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO
By Alex Philippidis, GEN Edge, June 14, 2026

Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments
By Alex Philippidis, GEN Edge, June 16, 2026

First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine Data
GEN, June 9, 2026

CRISPR Shreds Undruggable Cancer Cells with Precision
By Fay Lin, PhD, GEN Edge, June 8, 2026

New mRNA Delivery Platform Restores Muscle Function in DMD Models
GEN, June 11, 2026

Touching Base Podcast
Hosted by Corinna Singleman, PhD

Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD

The post Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine appeared first on GEN – Genetic Engineering and Biotechnology News.

What Butterfly’s saying about Midjourney’s ultrasonic CT plans

Generative artificial intelligence company Midjourney says it will open its first AI-powered medical imaging spa offering rapid whole-body, ultrasonic CT scans in 2027. “There is no radiation, no powerful magnetic fields – just sound and water and 60 seconds,” the company says about its Midjourney Medical plan. “It starts by stepping into a shallow pool…

The post What Butterfly’s saying about Midjourney’s ultrasonic CT plans appeared first on Medical Design and Outsourcing.

First Novel Antifungal for Aspergillus in 20 Years Succeeds in Phase III

F2G and Shionogi have reported positive Phase III results for the antifungal drug olorofim in patients with invasive aspergillosis who are not eligible for standard azole therapy. If approved based on this data, olorofim would become the first antifungal agent with a novel mechanism of action for invasive aspergillosis in over two decades. 

“Invasive fungal infections remain difficult to treat and can be life-threatening especially in immunocompromised patients,” said Johan Maertens, MD, PhD, professor of hematology at University Hospitals Leuven in Belgium and principal investigator of the study. “The OASIS topline results add to the growing body of evidence supporting olorofim’s therapeutic potential in a hard-to-treat population with limited antifungal options. We’re hopeful this could offer a meaningful alternative for clinicians to treat challenging infections caused by Aspergillus.”

Invasive aspergillosis is a fungal infection with high mortality rates that mainly affects immunocompromised patients. Due to rising drug resistance and toxicity profiles of currently available therapies, a growing number of patients cannot be treated with azole antifungals, leaving them with limited options. 

Olorofim belongs to a new class of antifungal agents called orotomides that was discovered by F2G. These drugs can selectively target an enzyme essential for the synthesis of pyrimidine that is shared across mold fungi including Aspergillus, making olorofim effective against a broad range of species including rare and drug-resistant strains. 

The Phase III OASIS study recruited 225 adults with invasive aspergillosis who either had a refractory infection or were unsuitable for azole therapy. Participants received either oral olorofim or amphotericin B—an antifungal used to treat serious infections known for causing kidney toxicity. 

After 42 days, the mortality rate among patients who took olorofim was 23.8%, compared to 24.3% for the control group. The rate of adverse events caused by the treatment was 35.8% for olorofim versus 63.9% for amphotericin B, with the difference being mostly driven by a higher rate of kidney toxicity in the control group. 

“This is a promising new development in antifungal medicine—an area where patients have been underserved for more than 20 years,” said John Keller, PhD, director of the board and senior vice president of R&D at Shionogi. “In current clinical practice, safety and tolerability considerations, particularly effects on renal function, can pose significant challenges for treatment selection and continuation. Against this background, the results of the OASIS study suggest that olorofim has the potential to offer a new treatment option for patients with invasive aspergillosis.” 

Based on these results, Shionogi and F2G plan to submit approval applications with regulatory authorities across the world. Under their commercial agreement, Shionogi will be responsible for commercialization in Europe and Asia, while F2G will oversee North America and other remaining territories. 

Over the past 20 years, most newly approved antifungal drugs have belonged to existing drug classes, limiting progress against the growing threat of antimicrobial resistance. During that period, only a single antifungal with a novel mechanism of action reached the market: ibrexafungerp, which is approved for the treatment of vulvovaginal candidiasis infections. If approved, olorofim would offer a much-needed option in an indication where both existing treatment choices and therapeutic innovation have historically remained limited. 

The post First Novel Antifungal for <i>Aspergillus</i> in 20 Years Succeeds in Phase III appeared first on Inside Precision Medicine.

Device developers win Junkosha Innovator of the Year Award prizes

Junkosha has named two medical device developers as Technology Innovator of the Year Award winners. Anchor Balloon Inc. founder and CEO Dr. Vishal Gupta won the $25,000 late phase award for the AngioLock coronary balloon catheter, described as a “zip-line catheter designed to stabilize and simplify precise stent delivery in complex coronary anatomy.” Junkosha also…

The post Device developers win Junkosha Innovator of the Year Award prizes appeared first on Medical Design and Outsourcing.